TL;DR: Researchers adapted a single-cell sequencing method called nbLIBRA-seq to link alpaca heavy-chain antibody sequences directly to antigen binding, recovering over 300 TfR1-specific antibodies from one blood sample and 1,125 RSV/hMPV-specific B cells in a multiplex test.

New method links sequence to specificity in alpacas

A team led by first-author Sabina Leonard reported a high-throughput platform for nanobody discovery in immunized alpacas, according to Cell Reports Methods.

The paper, titled Development and application of nbLIBRA-seq for high-throughput discovery of antigen-specific nanobodies, was published on Sept. 17, 2026.

The work came from the Vanderbilt Center for Antibody Therapeutics at Vanderbilt University Medical Center in Nashville, Tennessee, with co-authors from the Center for Computational Microbiology and Immunology, the Department of Biomedical Engineering and the Department of Chemical and Biomolecular Engineering, according to Cell Reports Methods.

Corresponding contact was listed for Ivelin Georgiev at Vanderbilt, with additional correspondence listed for an address at the University of Virginia, according to Cell Reports Methods.

Project lead Ivelin Georgiev described the effort as a collaboration with Kelsey Voss's group at the University of Virginia, in a Sept. 18, 2026 post.

The central claim was successful adaptation of linking B cell receptor to antigen specificity through sequencing, known as LIBRA-seq, to immunized alpacas for rapid identification of antigen-specific nanobodies derived from heavy-chain antibodies, according to Cell Reports Methods.

The authors framed nbLIBRA-seq as integration of antigen specificity with single-cell nanobody sequencing, according to Cell Reports Methods.

The stated purpose was scalable, high-throughput identification of antigen-specific nanobodies for diverse targets of interest from camelid immune repertoires, according to Cell Reports Methods.

Why nanobodies drew attention

Nanobodies are single-domain antibodies derived from heavy-chain-only antibodies produced naturally in camelids and sharks, according to Cell Reports Methods.

They resemble the heavy-chain variable region domains of human immunoglobulins, according to Cell Reports Methods.

They are described as the smallest known naturally occurring antigen-binding fragment, with potential for a variety of indications in pre-clinical and clinical studies, according to Cell Reports Methods.

Compared with canonical monoclonal IgG antibodies, the paper lists higher stability, increased tissue penetration and improved hydrophilicity while retaining high affinity to antigen, according to Cell Reports Methods.

A separate industry overview describes nanobodies as single-domain antibody fragments derived from heavy-chain-only antibodies present in members of the Camelidae family, including llamas, alpacas and camels, according to Genedata Selector reporting by Genedata.

That overview lists small size, high solubility and stability with an extended CDR3 region that can support strong antigen binding, according to Genedata.

Georgiev wrote that nanobodies are an up-and-coming therapeutic modality with numerous advantages over paired-chain antibodies for translational development and clinical use.

The Cell Reports Methods highlights list therapeutic, diagnostic and fundamental research applications as valuable uses for nanobodies.

The same highlights identify targets in infectious diseases and autoimmunity or cancer as proof-of-concept areas.

Other teams describe nanobodies as alternatives to classical antibodies in therapeutic and diagnostic contexts from parasites to bacteria to viruses, promising improved stability and simpler manufacturing, according to Communications Biology.

The Genedata overview lists oncology, inflammation, neurodegenerative disease and infectious disease research among areas of growing use.

Gap the team said it addressed

Nanobody discovery has been limited by laborious screening techniques, according to Cell Reports Methods.

Current workflows often rely on iterative screening or cannot directly link nanobody sequences with antigen specificity across diverse targets at scale, according to Cell Reports Methods.

The paper calls that limitation a methodological gap that restricts scalable profiling of antigen-specific nanobody responses and slows the pace of discovery, according to Cell Reports Methods.

Georgiev wrote that technology platforms for nanobody discovery have lagged behind, presenting a significant barrier to translation.

Traditional approaches such as phage display followed by Sanger sequencing support identification of dominant binders but typically capture only a limited subset of the library, according to Genedata.

As a result, low-abundance clones and broader diversity patterns can remain difficult to detect, according to Genedata.

Traditional clone isolation and Sanger sequencing examine hundreds of clones, representing only a limited snapshot of true library diversity, according to Genedata.

Valuable information about potent nanobodies may be overlooked when low-abundance clones become underrepresented during selection or sampling, according to Genedata.

Next-generation sequencing changes that paradigm by enabling deeper, repertoire-level analysis of nanobody libraries, according to Genedata.

By capturing both dominant and rare sequence variants, next-generation sequencing provides a more complete view of library composition and supports more rigorous candidate prioritization in early discovery, according to Genedata.

How nbLIBRA-seq works in outline

The method name expands to LIBRA-seq for nanobody discovery, according to Cell Reports Methods.

LIBRA-seq itself expands to linking B cell receptor to antigen specificity through sequencing, according to Cell Reports Methods.

The adaptation applies that linking approach to heavy-chain antibodies from immunized alpacas, according to Cell Reports Methods.

Georgiev described nanobody LIBRA-seq as a platform that enables high-throughput screening for nanobody candidates with target antigen specificity and cross-reactivity profiles directly from sequencing data.

The Cell Reports Methods highlights state that LIBRA-seq for nanobody discovery can identify antigen-specific nanobodies in alpaca.

The highlights also state that multiple antigens can be screened in the same library.

That multiplex property was presented as a route to scalable profiling across diverse targets of interest, according to Cell Reports Methods.

The authors said the capability will be critical for efficient development of nanobody-based therapeutics, according to Cell Reports Methods.

First validation: transferrin receptor from one sample

The team validated nbLIBRA-seq in two different disease settings, according to Cell Reports Methods.

First, the researchers identified over 300 antigen-specific heavy-chain antibodies against human transferrin receptor, abbreviated TfR1, from a single alpaca blood sample, according to Cell Reports Methods.

Human transferrin receptor was positioned in the infectious-disease and autoimmunity-or-cancer proof-of-concept program outlined in the highlights, according to Cell Reports Methods.

The single-sample result was used to demonstrate rapid identification without iterative screening, according to Cell Reports Methods.

The paper presents the TfR1 result as evidence that single-cell nanobody sequencing can recover hundreds of antigen-specific heavy-chain antibodies at once, according to Cell Reports Methods.

Second validation: RSV and hMPV fusion proteins together

Second, the team tested the efficiency of nbLIBRA-seq with multiple antigens in the screening library, according to Cell Reports Methods.

The test used fusion glycoproteins from the related respiratory syncytial virus, abbreviated RSV, and human metapneumovirus, abbreviated hMPV, according to Cell Reports Methods.

From that multiplex screen, 1,125 antigen-specific heavy-chain-expressing B cells were recovered, according to Cell Reports Methods.

The RSV and hMPV experiment was presented as a test of screening several antigens in the same library, according to Cell Reports Methods.

The relatedness of RSV and hMPV made the pair a test for specificity and cross-reactivity profiling within one workflow, as described in Georgiev's summary of target specificity and cross-reactivity profiles directly from sequencing data.

Georgiev said the validation applied nbLIBRA-seq to discovery of nanobody candidates against autoimmune and infectious disease targets.

He wrote that nbLIBRA-seq opens the door for rapid and effective development of novel nanobody-based therapeutics for a wide range of disease indications.

What single-cell adds over bulk screening

Bulk phage approaches typically identify dominant clones, while low-abundance candidates may be underrepresented or missed entirely, according to Genedata.

Next-generation sequencing expands the view by analyzing repertoires at greater depth, examining broader sequence diversity and comparing enrichment patterns, according to Genedata.

Instead of evaluating only selected clones, researchers can examine diversity, clonal enrichment and sequence composition throughout selection, according to Genedata.

Compared with clone-by-clone approaches, next-generation sequencing can generate orders of magnitude more sequence information from a single experiment, according to Genedata.

That depth makes it possible to track how repertoires evolve across selection rounds and to assess the impact of different screening conditions on library composition, according to Genedata.

The Cell Reports Methods team positioned single-cell linkage as the missing element, because bulk methods cannot directly link nanobody sequences with antigen specificity across diverse targets at scale, according to Cell Reports Methods.

The paper's motivation section says nbLIBRA-seq addresses that need by integrating antigen specificity with single-cell nanobody sequencing, according to Cell Reports Methods.

Parallel advance: NanoMAP at Tufts

A separate nanobody-repertoire study was published in Communications Biology on Sept. 16, 2026.

That study introduced an integrated experimental and computational pipeline called Nanobody Meta-clustering Analysis Platform, abbreviated NanoMAP, according to Communications Biology.

The Tufts University team included William L. White, Edward Moseley, Jacqueline M. Tremblay, Jackson N. Reilly, Akram A. Da'dara, Patrick J. Skelly, Lenore Cowen and Charles B. Shoemaker, according to Communications Biology.

Authors were affiliated with the Department of Computer Science in Medford, Massachusetts, and the Department of Infectious Disease and Global Health in North Grafton, Massachusetts, according to Communications Biology.

The team tested the pipeline on three distinct pools of targets, immunizing two alpacas with each pool and generating cDNA and phage display libraries from their immune repertoires, according to Communications Biology.

The researchers then panned the phage libraries on each target, according to Communications Biology.

To produce more detailed binding information, the team performed panning variations using subunits, natural variants, intact pathogens and binding site competitors, according to Communications Biology.

Deep sequencing reads from nanobody libraries before and after each panning were pooled and analyzed with NanoMAP to identify nanobody clonal families and assess levels of enrichment from the library in each panning, reflecting affinities, according to Communications Biology.

NanoMAP outperformed standard clustering methods, producing clonal families coherent in sequence and function and detecting rare but high-affinity families, according to Communications Biology.

By aggregating sequencing data within clonal families, NanoMAP produced reliable data on nanobody repertoire binding phenotypes for each antigen, according to Communications Biology.

The authors described the result as capability to functionally characterize a large fraction of immune-responsive nanobodies, permitting improved selection of nanobodies with desirable properties, according to Communications Biology.

The work acknowledged alpaca procurement, immunization, monitoring and bleeding support from Daniela Bedenice and Fionna Lehmann, according to Communications Biology.

Funding included NIH grants R01AI125704, R01AI056273 and R21AI173458 and 5K12GM133314-07, plus a seed grant from the Tufts Data Intensive Studies Center and a Tufts Springboard grant, according to Communications Biology.

Depth matters because frequency can mislead

Clone frequency does not necessarily correlate with functional performance, according to Genedata.

Some low-frequency variants may exhibit equal or even higher binding affinity than dominant clones, according to Genedata.

That finding makes sequencing depth a critical factor in identifying diverse and high-potential candidates, according to Genedata.

Sequencing at greater depth enables detection of low-abundance clones that would otherwise remain undetected, according to Genedata.

The NanoMAP authors similarly emphasized detection of rare but high-affinity families through family-level aggregation, according to Communications Biology.

Standardization push around VHH data

Another Sept. 16, 2026 report presented nanorepertoire, an end-to-end Nextflow DSL2 pipeline dedicated to camelid VHH repertoires, according to bioRxiv.

The authors were Davide Bagordo, Nicola Martelossi and Francesco Lescai of the University of Pavia, according to bioRxiv.

The paper describes camelid heavy-chain antibodies, and particularly their variable domains known as nanobodies or VHHs, as combining full antigen-binding capacity with a compact and highly stable scaffold, according to bioRxiv.

High-throughput adaptive immune receptor repertoire sequencing, abbreviated AIRR-seq, allows nanobody repertoires to be profiled at great depth, according to bioRxiv.

Analyses applied to VHH data are typically assembled ad hoc from standalone scripts, which limits standardization and reproducibility across laboratories, according to bioRxiv.

The proposed pipeline takes paired-end AIRR-seq FASTQ files through quality control, adapter trimming, read merging, in-silico translation, CD-HIT clonotyping and deep-learning CDR3 annotation with nanoCDR-X, according to bioRxiv.

It returns an interactive HTML report describing clonal architecture, CDR3 length and amino-acid composition, intra-clonal homogeneity and repertoire diversity, together with computational carbon footprint, according to bioRxiv.

Applied to two publicly available SARS-CoV-2 RBD-selected llama libraries sampled before and after phage-display enrichment, totaling 4.8 million paired-end reads, the pipeline completed in 59 minutes on a 16-vCPU cloud instance and recovered 41,363 distinct CDR3 paratopes, according to bioRxiv.

The test reproduced the expected contraction of clonal diversity upon selection, according to bioRxiv.

The code was released open source under the MIT licence and archived on Zenodo, with operation unchanged on local, HPC and cloud infrastructures, according to bioRxiv.

Who did what on nbLIBRA-seq

First authorship was held by Sabina Leonard of the Vanderbilt Center for Antibody Therapeutics, according to Cell Reports Methods.

Additional listed contributors included Perry T. Wasdin, Katherine Webb, Parastoo Amlashi and Chloe Renken, according to Cell Reports Methods.

Wasdin held appointments in the Vanderbilt Center for Antibody Therapeutics and the Center for Computational Microbiology and Immunology, according to Cell Reports Methods.

Webb was affiliated with the Department of Biomedical Engineering at Vanderbilt University, according to Cell Reports Methods.

The collaboration statement credited Kelsey Voss's group at the University of Virginia alongside Leonard's lead role.

What remains a research tool

The Cell Reports Methods paper describes demonstration of successful adaptation and validation in two disease settings, not a therapeutic approval, according to Cell Reports Methods.

The reported outputs were antigen-specific heavy-chain antibodies and heavy-chain-expressing B cells with sequence-linked specificity, according to Cell Reports Methods.

The authors frame those outputs as starting points that will be critical for efficient development of nanobody-based therapeutics, according to Cell Reports Methods.

Georgiev framed the platform as opening the door for rapid and effective development of novel therapeutics for a wide range of disease indications, without naming a clinical candidate.

For readers tracking methods, the three September reports together outline distinct layers: single-cell linkage of sequence to specificity, family-level functional mapping of full repertoires, and standardized VHH processing, according to Cell Reports Methods, Communications Biology and bioRxiv.

Sources referenced